In a recent episode of the PharmaSource podcast, Arul Ramadurai, Chief Commercial Officer at Axplora, discusses the company’s strategic focus on high-growth therapeutic areas and its customer-driven investment philosophy.
Strategic Focus on High-Growth Therapeutic Areas
Axplora has positioned itself in two of the fastest-growing therapeutic areas: GLP-1 peptides and antibody-drug conjugates (ADCs). The company recently announced a €50 million investment in itsMourenx site in Southwest France for GLP-1 manufacturing capabilities. This investment enhances the site’s position as a center of excellence for contract manufacturing of APIs and drug substances for FDA-approved biologics.
In the ADC space, Axplora’s dominance is clear. They currently supply 40% of the world’s marketed ADCs and 50% of FDA-approved ADCs, making them a global leader. The company recently announced a new cutting-edge payload manufacturing workshop at their Le Mans site to further strengthen this position.
Customer-Driven Investment Philosophy
Axplora’s expansion strategy is distinctly customer-led rather than speculative. The company works closely with customers in North America, Europe, and Asia to develop solutions for capacity needs in the coming years. This approach has led to multiple strategic investments across Europe, including expansions at the Mourenx site, a new workshop for ADCs in Le Mans, and ongoing investments in Leverkusen, Germany.
Technical Expertise as a Competitive Advantage
Axplora’s technical edge in both GLP-1 and ADC manufacturing stems from its heritage. The company’s history in chromatography, particularly from the Novasep business, positions it as a leader in purification processes. This expertise is critical in manufacturing complex molecules like GLP-1s and ADCs, which require advanced purification and industrial chemistry capabilities.
To listen to the full podcast episode, visit: Axplora Strategy Teardown: Investing in High-Growth Therapeutics with a Customer-Driven Approach
Latest news
News
March 17, 2026
Biopharma’s Growing Emphasis on Highly Potent Drugs Drives Axplora Manufacturing Expansion
Highly potent drugs now account for over 30% of the global pipeline, with more than 1,000 molecules in development — Axplora’s investments in HPAPI capacity help customers bring these complex therapies to market faster $60 million investment to expand highly potent API (HPAPI) development and manufacturing at Axplora’s Farmabios site in Gropello Cairoli, Italy New […]
News
March 17, 2026
Axplora announces multi-million-euro investment to expand lyophilization at Le Mans and appoints François Houbart as Head of Site
Axplora announces multi-million-euro investment to expand lyophilization at Le Mans and appoints François Houbart as Head of Site 18 February, 2026 – Axplora, a global CDMO Partner for complex small molecules and antibody-drug conjugates (ADCs), today announced a multi-million-euro investment to expand lyophilization (freeze-drying) capabilities at its Le Mans, France Site strengthening its ability to deliver […]
Press Release
October 08, 2025
Axplora initiates global investments exceeding €100m in 2025
Raubling, 7 October, 2025 – Axplora, a global leader in small molecule API manufacturing and a trusted partner to the world’s most innovative pharmaceutical companies, today announced that the total investments initiated across its global network in 2025 will exceed €100 million. This commitment underscores Axplora’s determination to accelerate growth, strengthen capabilities, and reinforce its […]
We enable our partners to fully realize their ambitions.
Driven by the curiosity, skills and dedication of over 2,000 employees on three continents, Axplora delivers sustainable, technologically advanced API solutions to improve lives worldwide.